Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230273 | 1.00 | ADORA1 (0.70) | ADORA1ADORA2AADORA3ADORA2BHTR2C | |
| SCHEMBL3913337 | 1.00 | ADORA1 (0.70) | ADORA1ADORA2AADORA3ADORA2BHTR2C | |
| SCHEMBL2832621 | 1.00 | ADORA1 (0.70) | ADORA1ADORA2AADORA3ADORA2BHTR2C | |
| SCHEMBL4618979 | 0.94 | ADORA1 (0.72) | ADORA1ADORA2AADORA3ADORA2BHTR2C | |
| SCHEMBL6841625 | 0.90 | ADORA2A (0.56) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL6876893 | 0.90 | ADORA1 (0.56) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL6838893 | 0.90 | ADORA1 (0.58) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL3914192 | 0.88 | ADORA3 (0.58) | ADORA1ADORA2AADORA3ADORA2BHTR2C | |
| SCHEMBL3914182 | 0.88 | ADORA3 (0.58) | ADORA1ADORA2AADORA3ADORA2BHTR2C | |
| SCHEMBL8090571 | 0.88 | ADORA3 (0.58) | ADORA1ADORA2AADORA3ADORA2BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA1 3/4885ADORA2A 1/4885ADORA3 2/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | ADORA1 838/4885ADORA2A 2314/4885ADORA3 545/4885 |
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.